The PReSUTINeB study is now live, addressing the number four priority from the Spinal Cord Injury Priority Setting Partnership.
Damage to the spinal cord results in the impairment of several other organs, including the bladder, which ceases to control urine effectively and requires constant management and intervention. The risk of a Urinary Tract Infection is very high and on average, people with spinal cord injury suffer two-and-a-half urinary tract infections every year. Stoke Mandeville Spinal Research, in collaboration with clinical specialists from the Thames Valley, is researching the effectiveness of a new pro-biotic vaccine to help with the problem. The research is funded by the National Institute for Health Research, Research for Patient Benefit Programme.
To find out more, please visit http://www.lifeafterparalysis.com/presutineb/
The inclusion criteria for the study are:
- Participant having a loss of bladder control due to a Spinal Injury (including Cauda Equina Syndrome and Transverse Myelitis) or Multiple Sclerosis
- Participant having least one year since their current neurological condition was confirmed by their medical doctor and that they are now living in the community
- Participant's current neurological condition has now been stable for the last 9 months, and this has been confirmed by their treating physician
- Participant aged between 18 to 75 years (male or female)
- Participant suffered at least three symptomatic Urinary Tract Infections within the last twelve months or two symptomatic Urinary Tract Infections within the last six months, all of which have been treated by antibiotics
- Participant able provide Written Informed Consent, complete questionnaires and undertake Interview Questions.
By taking part, patients will be helping to improve understanding of Urinary Tract Infections and inform future treatment of this debilitating condition.